Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio‐Renal‐Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study
Journal of Diabetes · 2026
DOI: 10.1111/1753-0407.70227 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Jijie Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Renal Insufficiency, Chronic, Atherosclerosis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardio‐renal‐metabolic (CRM) multimorbidity, defined by the co‐occurrence of cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes (T2DM), poses a growing burden for multimorbidity management. The atherogenic index of plasma (AIP), a lipid‐based marker of insulin resistance, may help predict CRM progression, but its prognostic value remains unclear.
Methods
We used data from 5805 adults free of CRM at baseline in the China Health and Retirement Longitudinal Study. AIP was calculated as log 10 [triglyceride (TG)/high‐density lipoprotein cholesterol (HDL‐C)]. CRM onset was defined as incident CVD, T2DM, or CKD. Multistate models captured transitions from no disease to single, dual, and triple CRM states. Cox regression and time‐dependent receiver operating characteristic (ROC) curves were used to assess associations and predictive performance.
Results
AIP showed a clear dose–response relationship with CRM progression. Each 1‐standard deviation (SD) increase in AIP was associated with higher risks of single (HR 1.17, 95% CI 1.13–1.22), dual (HR 1.31, 95% CI 1.21–1.41), and triple CRM (HR 1.57, 95% CI 1.27–1.94) diseases. Strong associations were observed for new‐onset T2DM and stroke, but not CKD. AIP yielded the highest discrimination for triple CRM (5‐year area under the curve [AUC] = 0.710). Multistate modeling showed each 1‐SD increase in AIP raised the hazard of transitioning from single to dual CRM by 14% and from dual to triple by 31%.
Conclusions
AIP is an independent, simple, and low‐cost predictor of CRM onset and progression, with potential utility for early risk stratification and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
- College of Nursing, Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Xiufang Lin
Zitieren
APA
Jin, J., Wang, F., Chen, S., Shao, J., Chen, B., & Lin, X. (2026). Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio‐Renal‐Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70227
Vancouver
Jin J, Wang F, Chen S, Shao J, Chen B, Lin X. Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio‐Renal‐Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70227
BibTeX
@article{Jin2026,
author = {Jin, Jijie and Wang, Fei and Chen, Shengzhang and Shao, Jiaxin and Chen, Binyan and Lin, Xiufang},
title = {Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio‐Renal‐Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study},
journal = {Journal of Diabetes},
year = {2026},
doi = {10.1111/1753-0407.70227}
}
EUVIMED